Barr's bid for biogenerics line seen as risky by some

09/16/2006 | CNNMoney

Stock analysts are labeling as "risky" the $2.5 billion bid Barr Pharmaceuticals has made for the Croatian Pliva to get access to its biogenerics drug line. Some called the bid by the U.S. generics maker "speculative" for an industry still in early stages of development. Competing bidder Actavis, of Iceland, has until Sept. 27 to top Barr's bid.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ